Evidence map›Paper›PMID 32453071›Full record

ArticleJournal of cardiovascular pharmacology2020

The Small Conductance Calcium-Activated Potassium Channel Inhibitors NS8593 and UCL1684 Prevent the Development of Atrial Fibrillation Through Atrial-Selective Inhibition of Sodium Channel Activity.

Alexander Burashnikov, Hector Barajas-Martinez, Dan Hu, Victoria M Robinson, Morten Grunnet, Charles Antzelevitch

Open access · hybridAbstract readComparative Study
In one paragraph

Article in Journal of cardiovascular pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Small-conductance CaThe Journal of physiology · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Effective termination of atrial fibrillation by SK channel inhibition is associated with a sudden organization of fibrillatory conduction.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2021
    Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 3 countries.

Alexander BurashnikovLakenau Institute for Medical Research, Wynnewood, PA.
Hector Barajas-MartinezLakenau Institute for Medical Research, Wynnewood, PA.
Dan HuRenmin Hospital of Wuhan University, Wuhan, China.
Victoria M RobinsonLakenau Institute for Medical Research, Wynnewood, PA.
Morten GrunnetAcesion Pharma, Copenhagen, Denmark.
Charles AntzelevitchLakenau Institute for Medical Research, Wynnewood, PA.
Acesion Pharma (Denmark) · DKLankenau Heart Institute · USLankenau Institute for Medical Research · USMasonic Medical Research Laboratory · USRenmin Hospital of Wuhan University · CNThomas Jefferson University · US

Funding

ELECTRICAL HETEROGENEITY AND CARDIAC ARRHYTHMIASR01HL047678 · NHLBI · MASONIC MEDICAL RESEARCH LABORATORY, INC · PI ANTZELEVITCH, CHARLES · 1993 to 2014
$5.7M
Development of a whole heart model of the J wave syndromes and novel approaches to pharmacologic management of associated life-threatening arrhythmiasR01HL152201 · NHLBI · LANKENAU INSTITUTE FOR MEDICAL RESEARCH · PI ANTZELEVITCH, CHARLES, DI DIEGO, JOSE M. · 2020 to 2023
$2.5M
Novel Approaches to Pharmacologic Management of Life-Threatening Arrhythmias Associated with the J Wave SyndromesR56HL138103 · NHLBI · LANKENAU INSTITUTE FOR MEDICAL RESEARCH · PI ANTZELEVITCH, CHARLES · 2018 to 2018
$413k
NHLBI NIH HHS R01 HL047678NHLBI NIH HHS R01 HL152201NHLBI NIH HHS R56 HL138103
6 · The paper itself

Abstract

The mechanisms underlying atrial-selective prolongation of effective refractory period (ERP) and suppression of atrial fibrillation (AF) by NS8593 and UCL1684, small conductance calcium-activated potassium (SK) channel blockers, are poorly defined. The purpose of the study was to confirm the effectiveness of these agents to suppress AF and to probe the underlying mechanisms. Transmembrane action potentials and pseudoelectrocardiograms were recorded from canine isolated coronary-perfused canine atrial and ventricular wedge preparations. Patch clamp techniques were used to record sodium channel current (INa) in atrial and ventricular myocytes and human embryonic kidney cells. In both atria and ventricles, NS8593 (3-10 µM) and UCL1684 (0.5 µM) did not significantly alter action potential duration, suggesting little to no SK channel inhibition. Both agents caused atrial-selective: (1) prolongation of ERP secondary to development of postrepolarization refractoriness, (2) reduction of Vmax, and (3) increase of diastolic threshold of excitation (all are sodium-mediated parameters). NS8593 and UCL1684 significantly reduced INa density in human embryonic kidney cells as well as in atrial but not in ventricular myocytes at physiologically relevant holding potentials. NS8593 caused a shift of steady-state inactivation to negative potentials in atrial but not ventricular cells. NS8593 and UCL1684 prevented induction of acetylcholine-mediated AF in 6/6 and 8/8 preparations, respectively. This anti-AF effect was associated with strong rate-dependent depression of excitability. The SK channel blockers, NS8593 and UCL1684, are effective in preventing the development of AF due to potent atrial-selective inhibition of INa, causing atrial-selective prolongation of ERP secondary to induction of postrepolarization refractoriness.

Indexed as

1-NaphthylamineAction PotentialsAlkanesAnimalsAnti-Arrhythmia AgentsAtrial FibrillationDogsFemaleHeart AtriaHeart RateHeart VentriclesHEK293 CellsHumansMaleMyocytes, CardiacNAV1.5 Voltage-Gated Sodium Channel1-Naphthylamine6,10-diaza-3(1,3),8(1,4)dibenzena-1,5(1,4)diquinolinacyclodecaphaneAlkanesAnti-Arrhythmia AgentsNAV1.5 Voltage-Gated Sodium ChannelPotassium Channel BlockersQuinolinium Compounds(R)-N-(benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphthylamineSCN5A protein, humanSmall-Conductance Calcium-Activated Potassium ChannelsSodium Channel Blockers

Identifiers

PMID32453071
PMCPMC7416459
OpenAlexW3029610719

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.